UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 57

Sortiert nach

High expression of Wee1 is associated with poor disease-free survival in malignant melanoma: potential for targeted therapy

PloS one, 2012-06, Vol.7 (6), p.e38254-e38254

2012

Volltextzugriff (PDF)

Aminopeptidase Expression in Multiple Myeloma Associates with Disease Progression and Sensitivity to Melflufen

Cancers, 2021-03, Vol.13 (7), p.1527

2021

Volltextzugriff (PDF)

MX 2 is a novel regulator of cell cycle in melanoma cells

Pigment cell and melanoma research, 2020-05, Vol.33 (3), p.446-457

2020

Volltextzugriff (PDF)

Expression and clinical role of DJ-1, a negative regulator of PTEN, in ovarian carcinoma

Human pathology, 2008, Vol.39 (1), p.87-95

2008

Volltextzugriff (PDF)

Targeting aggressive osteosarcoma with a peptidase-enhanced cytotoxic melphalan flufenamide

Therapeutic advances in medical oncology, 2020, Vol.12, p.1758835920937891-1758835920937891

2020

Volltextzugriff (PDF)

Novel Peptide‐drug Conjugate Melflufen Efficiently Eradicates Bortezomib‐resistant Multiple Myeloma Cells Including Tumor‐initiating Myeloma Progenitor Cells

HemaSphere, 2021-07, Vol.5 (7), p.e602-n/a

2021

Volltextzugriff (PDF)

MX2 mediates establishment of interferon response profile, regulates XAF1, and can sensitize melanoma cells to targeted therapy

Cancer medicine (Malden, MA), 2021-04, Vol.10 (8), p.2840-2854

2021

Volltextzugriff (PDF)

Metabolic reprogramming is associated with flavopiridol resistance in prostate cancer DU145 cells

Scientific reports, 2017-07, Vol.7 (1), p.5081-20, Article 5081

2017

Volltextzugriff (PDF)

KIT in Melanoma: Many Shades of Gray

Journal of investigative dermatology, 2015-02, Vol.135 (2), p.337-338

2015

Volltextzugriff (PDF)

PB2071: SENSITIVITY OF MULTIPLE MYELOMA TO MELFLUFEN ASSOCIATES WITH DECREASED P53 ACTIVITY AND ENRICHMENT OF DNA DAMAGE REPAIR PATHWAY GENES

HemaSphere, 2023-08, Vol.7 (S3), p.e9358540

2023

Volltextzugriff (PDF)

P598: DISRUPTION IN ONE‐CARBON METABOLISM THROUGH MTHFD1 INHIBITION AS NOVEL THERAPEUTIC STRATEGY IN CHRONIC LYMPHOCYTIC LEUKEMIA

HemaSphere, 2023-08, Vol.7 (S3), p.e7000496-n/a

2023

Volltextzugriff (PDF)

Melflufen, a peptide‐conjugated alkylator, is an efficient anti‐neo‐plastic drug in breast cancer cell lines

Cancer medicine (Malden, MA), 2020-09, Vol.9 (18), p.6726-6738

2020

Volltextzugriff (PDF)

Expression of CDK1(Tyr15), pCDK1(Thr161), Cyclin B1 (total) and pCyclin B1(Ser126) in vulvar squamous cell carcinoma and their relations with clinicopatological features and prognosis

PloS one, 2015, Vol.10 (4), p.e0121398-e0121398

2015

Volltextzugriff (PDF)

The fatty acid binding protein 7 (FABP7) is involved in proliferation and invasion of melanoma cells

BMC cancer, 2008-09, Vol.8 (1), p.276-276, Article 276

2008

Volltextzugriff (PDF)

Melphalan flufenamide inhibits osteoclastogenesis by suppressing proliferation of monocytes

Bone Reports, 2021-12, Vol.15, p.101098-101098, Article 101098

2021

Volltextzugriff (PDF)

Growth Response and Differentiation of Bone Marrow-Derived Mesenchymal Stem/Stromal Cells in the Presence of Novel Multiple Myeloma Drug Melflufen

Cells (Basel, Switzerland), 2022-05, Vol.11 (9), p.1574

2022

Volltextzugriff (PDF)

Mir-29a is a candidate biomarker of better survival in metastatic high-grade serous carcinoma

Human pathology, 2016-08, Vol.54, p.74-81

2016

Volltextzugriff (PDF)

The Peptide–Drug Conjugate Melflufen Modulates the Unfolded Protein Response of Multiple Myeloma and Amyloidogenic Plasma Cells and Induces Cell Death

HemaSphere, 2022-03, Vol.6 (3), p.e687-n/a

2022

Volltextzugriff (PDF)

Cytoplasmic BRMS1 expression in malignant melanoma is associated with increased disease-free survival

BMC cancer, 2012-02, Vol.12 (1), p.73-73, Article 73

2012

Volltextzugriff (PDF)

Biological effects induced by insulin‐like growth factor binding protein 3 (IGFBP‐3) in malignant melanoma

International journal of cancer, 2010-01, Vol.126 (2), p.350-361

2010

Volltextzugriff (PDF)

Diagnostic and prognostic role of the insulin growth factor pathway members insulin-like growth factor-II and insulin-like growth factor binding protein-3 in serous effusions

Human pathology, 2009-04, Vol.40 (4), p.527-537

2009

Volltextzugriff (PDF)

Effect of ABCB1 Multidrug Resistance Protein on Efficacy of Anti-Myeloma Drugs in Carfilzomib-Resistant Myeloma Model

Blood, 2020-11, Vol.136 (Supplement 1), p.36-37

2020

Volltextzugriff (PDF)

Up-regulation of multidrug resistance protein MDR1/ABCB1 in carfilzomib-resistant multiple myeloma differentially affects efficacy of anti-myeloma drugs

Leukemia research, 2021-02, Vol.101, p.106499, Article 106499

2021

Volltextzugriff (PDF)

A Potential Role of NK Cells and ABCB9 in Modulating the Response to Melflufen in Multiple Myeloma

Blood, 2022-11, Vol.140 (Supplement 1), p.6000-6001

2022

Volltextzugriff (PDF)

Abstract C056: MIV-818 stimulates an antitumor immune response in vitro and enhances the effects of pembrolizumab

Molecular cancer therapeutics, 2019-12, Vol.18 (12_Supplement), p.C056-C056

2019

Volltextzugriff (PDF)

1 – 25 von 57

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(56)
Mit Volltextzugriff
(54)

Publikationsform

Artikel
(56)
Buchkapitel
(1)

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Blood
(6)
Cancer Medicine
(6)
Hemasphere
(5)
American Journal Of Clinical Pathology
(4)
Pigment Cell And Melanoma Research
(4)
Plos One
(4)
Bmc Cancer
(3)
Cancer Research
(3)
Human Pathology
(3)
International Journal Of Cancer
(2)

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

High expression of Wee1 is associated with poor disease-free survival in malignant melanoma: potential for targeted therapy

Aminopeptidase Expression in Multiple Myeloma Associates with Disease Progression and Sensitivity to Melflufen

MX 2 is a novel regulator of cell cycle in melanoma cells

Expression and clinical role of DJ-1, a negative regulator of PTEN, in ovarian carcinoma

Targeting aggressive osteosarcoma with a peptidase-enhanced cytotoxic melphalan flufenamide

Novel Peptide‐drug Conjugate Melflufen Efficiently Eradicates Bortezomib‐resistant Multiple Myeloma Cells Including Tumor‐initiating Myeloma Progenitor Cells

MX2 mediates establishment of interferon response profile, regulates XAF1, and can sensitize melanoma cells to targeted therapy

Metabolic reprogramming is associated with flavopiridol resistance in prostate cancer DU145 cells

KIT in Melanoma: Many Shades of Gray

PB2071: SENSITIVITY OF MULTIPLE MYELOMA TO MELFLUFEN ASSOCIATES WITH DECREASED P53 ACTIVITY AND ENRICHMENT OF DNA DAMAGE REPAIR PATHWAY GENES

P598: DISRUPTION IN ONE‐CARBON METABOLISM THROUGH MTHFD1 INHIBITION AS NOVEL THERAPEUTIC STRATEGY IN CHRONIC LYMPHOCYTIC LEUKEMIA

Melflufen, a peptide‐conjugated alkylator, is an efficient anti‐neo‐plastic drug in breast cancer cell lines

Expression of CDK1(Tyr15), pCDK1(Thr161), Cyclin B1 (total) and pCyclin B1(Ser126) in vulvar squamous cell carcinoma and their relations with clinicopatological features and prognosis

The fatty acid binding protein 7 (FABP7) is involved in proliferation and invasion of melanoma cells

Melphalan flufenamide inhibits osteoclastogenesis by suppressing proliferation of monocytes

Growth Response and Differentiation of Bone Marrow-Derived Mesenchymal Stem/Stromal Cells in the Presence of Novel Multiple Myeloma Drug Melflufen

Mir-29a is a candidate biomarker of better survival in metastatic high-grade serous carcinoma

The Peptide–Drug Conjugate Melflufen Modulates the Unfolded Protein Response of Multiple Myeloma and Amyloidogenic Plasma Cells and Induces Cell Death

Cytoplasmic BRMS1 expression in malignant melanoma is associated with increased disease-free survival

Biological effects induced by insulin‐like growth factor binding protein 3 (IGFBP‐3) in malignant melanoma

Diagnostic and prognostic role of the insulin growth factor pathway members insulin-like growth factor-II and insulin-like growth factor binding protein-3 in serous effusions

Effect of ABCB1 Multidrug Resistance Protein on Efficacy of Anti-Myeloma Drugs in Carfilzomib-Resistant Myeloma Model

Up-regulation of multidrug resistance protein MDR1/ABCB1 in carfilzomib-resistant multiple myeloma differentially affects efficacy of anti-myeloma drugs

A Potential Role of NK Cells and ABCB9 in Modulating the Response to Melflufen in Multiple Myeloma

Abstract C056: MIV-818 stimulates an antitumor immune response in vitro and enhances the effects of pembrolizumab

Suchergebnisse filtern